OMCL
Omnicell, Inc.44.74
+1.47+3.4%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Titan XT ignites competitive pipeline
Q&A revealed early Titan XT traction firing up a vibrant competitive pipeline, with management baking a modest 2026 bookings step-up into guidance despite similar pacing to XT's eight-year cycle. XT Xtend buyers access Omnisphere cloud without stranded costs, while new Omnicell leasing keeps deals alive against rivals' structures. Salesforce and clinical investments ramp for the pivot; Q4 margins dipped on mix and $6M tariffs, with $15M eyed for 2026 but mitigations progressing. Competitive wins accelerate. Platform recurring revenue beckons; watch share grabs.
Key Stats
Market Cap
2.06BP/E (TTM)
104.05Basic EPS (TTM)
0.43Dividend Yield
0%Recent Filings
10-K
FY2025 results
Omnicell posted FY2025 revenue of $1.18B, up 7% y/y, with product sales climbing 6% on XTExtend strength while services surged 8% from technical support growth and specialty pharmacy demand. Q4 drove momentum as ARR hit $636M (up 10% y/y), signaling robust recurring streams amid XT lifecycle normalization. Gross margins held steady at 42% despite tariff hits, but operating expenses rose on headcount and commissions, yielding slim $2M net income. Cash fell to $197M after $175M note repayment and $78M buybacks, yet $350M revolver stands untapped. Delays in installations risk quarterly bookings.
8-K
Solid Q4 results, Titan XT launch
Omnicell reported Q4 2025 revenues of $314M, up 2% year-over-year, with full-year total hitting $1.185B, a 7% rise fueled by services and consumables. ARR climbed to $636M from $580M, yet product bookings dipped 4% amid the XT upgrade cycle's end. Titan XT launched to extend automation into nursing. 2026 guides $1.215B-$1.255B revenues. Cash sits at $197M.
8-K
Titan XT launch announced
Omnicell launched Titan XT on December 8, 2025, its next-gen automated dispensing system powered by OmniSphere to enable autonomous medication management across enterprises. It boosts pharmacy control via DynamicRestock and AI inventory predictions while simplifying nurse workflows with FiveRights safeguards. Titan XT is available now in the US. Forward-looking benefits face execution risks like market demand shifts.
10-Q
Q3 FY2025 results
Omnicell posted Q3 revenues of $310.6M, up 10% y/y from $282.4M, with product sales jumping 12% on XTExtend strength while services grew 7% on technical support and SaaS demand; gross margin held at 43% despite tariff hits and service cost hikes. Operating income hit $8.2M, up from $6.6M y/y, driving diluted EPS of $0.12 (reconciles to 45.9M shares). Cash from operations tallied $97M YTD, less last year's $131M after $175M note repayment and $78M buybacks; $180M cash remains with $350M revolver available and $167M 2029 notes at 1%. Repaid 2025 notes fully. Tariffs crimp supply costs.
8-K
Q3 revenues beat, guidance raised
Omnicell posted Q3 2025 revenues of $311 million, up 10% from last year, beating guidance across metrics with non-GAAP EBITDA at $41 million. Connected devices fueled the surge, while the firm repaid $175 million in notes and repurchased $62 million in shares. It raised full-year revenue guidance to $1.177-$1.187 billion. Cash sits at $180 million.
IPO
Website
Employees
Sector
Industry
CCLD
CareCloud, Inc.
3.21+0.02
CMHSF
COMPREHENSIVE HEALTHCARE SYS IN
0.35+0.00
MCK
McKesson Corporation
809.96-13.05
MNDR
Mobile-health Network Solutions
1.08+0.02
OMC
Omnicom Group Inc.
80.64+0.16
OMDA
Omada Health, Inc.
14.61+0.02
OMI
Owens & Minor, Inc.
3.10+0.09
OMQS
OMNIQ Corp.
0.12-0.01
ONMD
OneMedNet Corp
1.41+0.17
TDOC
Teladoc Health, Inc.
7.41+0.07